Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most research has been done, costs less than $20 per dose. Research shows that intranasal esketamine is less effective and has more unwanted effects than injected ketamine, yet the approval means that this intranasal formulation will now be the form used and researched.
Conclusion
While the approval of an inferior treatment mode is understandable from the processes by which medicines are approved, we should think carefully about embracing this particular form of a promising treatment.
StewartACPeacockADjordjevicF, et al.Ketamine use among people who regularly use ecstasy and other illicit stimulants in Australia: trends and characteristics of use, 2009–2019. J Stud Alcohol Drugs2021; 82(2): 188–196.
2.
AndradeC. Ketamine for depression, 3: does chirality matter?J Clin Psychiatry2017; 78(6): e674–e677.
3.
WeiYChangLHashimotoK. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry. Published online May 7, 2021.
4.
BonaventuraJLamSCarltonM, et al.Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. Published online April 15, 2021.
5.
GastaldonCRaschiEKaneJM, et al.Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom. 2021;90(1):41–48.
6.
Correia-MeloFSSilvaSSAraújo-de-FreitasL, et al.S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Rev Bras Psiquiatr2017; 39(2): 188–189.
7.
VlerickLDevreeseMPeremansK, et al.Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. PLoS One2020; 15(1): e0227762–e0227762.
8.
GálvezVLiAHugginsC, et al.Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol2018; 32(4): 397–407.
9.
BahjiAVazquezGHZarateCA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord2021; 278: 542–555.
